Back to School: How biopharma can reboot drug development. Access exclusive analysis here

July 16 Quick Takes: Biotech stocks fare worse than others in STAR tumble; plus BioAtla, Exalys, Virometix, Biose, Spirea

Biotechs on STAR suffer amid broader sell-off
As concerns about the COVID-19 outbreak and a mixed recovery outlook rattled stocks traded in Shanghai, biotech stocks on the STAR exchange generally fared worse than the Shanghai Composite Index’s 4.5% downturn

Read the full 381 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers